VAQTA 25 [iU]/.5mL

VAQTA 25 [iU]/.5mL is an inactivated hepatitis A vaccine designed to prevent hepatitis A virus infection. This intramuscular injection is suitable for individuals seeking protection against hepatitis A, a viral liver disease.

VAQTA 25 [iU]/.5mL is primarily used for the prevention of hepatitis A, a contagious liver infection caused by the hepatitis A virus. This vaccine is often recommended for individuals who are at higher risk of exposure, such as travelers to regions with high rates of hepatitis A, as well as for those with certain medical conditions or lifestyle factors that increase their risk. The vaccine works by stimulating the body's immune system to produce antibodies against the hepatitis A virus, providing long-lasting protection.

Common effects of VAQTA 25 [iU]/.5mL may include mild soreness, redness, or swelling at the injection site. Some individuals might experience temporary fatigue, headache, or low-grade fever following vaccination. These effects are generally mild and short-lived, resolving on their own within a few days.

VAQTA 25 [iU]/.5mL should be administered by a healthcare professional. Individuals with a history of severe allergic reactions to any component of the vaccine, including neomycin, should avoid this vaccine. It is important to inform your healthcare provider about any current illnesses or allergies before receiving the vaccine.

VAQTA 25 [iU]/.5mL may interact with certain medications or other vaccines. It is advisable to discuss your current medication regimen with a healthcare provider before receiving this vaccine. Additionally, individuals who are immunocompromised or taking immunosuppressive therapies should consult their healthcare provider for personalized advice.